Drug Profile
JTT 552
Alternative Names: JTT-552Latest Information Update: 23 Jul 2009
Price :
$50
*
At a glance
- Originator Japan Tobacco
- Class Antigouts
- Mechanism of Action SLC22A12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperuricaemia
Most Recent Events
- 31 Mar 2009 Discontinued - Phase-II for Hyperuricaemia in Japan (PO)
- 28 Nov 2006 Phase-I clinical trials in Hyperuricaemia in Japan (unspecified route)